Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, et al. Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01. Eur J Cancer 2024;213:115117.
PMID: 39522333